Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Case Report

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B

Eun Hye Kim, Hana Park, Kun Ho Lee, Sang Hoon Ahn, Seung-Min Kim, Kwang-Hyub Han

Clin Mol Hepatol. 2013;19(1):82-86. Published online March 25, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.1.82

View: 7308 Download: 86 Web of Science: 8 Crossref: 10

4

A case of sudden-onset hearing Loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C

Min Ki Shin , Tae Hyo Kim , Kang Ju , Chang Yoon Ha , Hyun Ju Min , Woon Tae Jung , Ok Jae Lee

Clin Mol Hepatol. 2009;15(3):370-374. Published online September 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.3.370

View: 4856 Download: 25 Crossref: 3

Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C

Hyung Min Kang, M.D., Myung Jin Park, M.D. Jeong-Min Hwang, M.D. Jin Wook Kim, M.D., Sook-Hyang Jeong, M.D.

Clin Mol Hepatol. 2009;15(2):209-215. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.209

View: 4840 Download: 37 Crossref: 3

3

Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients Living in Daejeon and Chungcheong Province in Korea: A comparative study

Jeong Il Kim, M.D, Seok Hyun Kim, M.D., Byung Seok Lee, M.D., Heon Young Lee, M.D., Tae Hee Lee, M.D. Young Woo Kang, M.D. Hyang Ie Lee, M.D. An Na Kim, M.D. Soon Woo Nam, M.D. Byeong Chool Park, M.D. Hee Bok Chae, M.D. Seok Bae Kim, M.D. Il Han Song, M.D. Ji Young Park, M.D. Hong Su Kim, M.D.

Clin Mol Hepatol. 2008;14(4):493-502. Published online December 31, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.4.493

View: 4732 Download: 21 Crossref: 9

4

Pulmonary Toxicity by Pegylated Interferon α-2a in a Patient with Chronic Hepatitis C

Byoung Kwan Son , Joo Hyun Sohn , Tae Yeob Kim , Yoon Kyung Park , Yong Chul Jeon , Dong Soo Han

Clin Mol Hepatol. 2007;13(1):103-107. Published online January 1, 1970

View: 2900 Download: 19

1 |

Viewed By 5097	MAFLD: How is it different from NAFLD?
Viewed By 5072	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4498	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4472	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4363	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 138	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search